Data showed that early treatment of Copaxone reduced the risk for developing definite multiple sclerosis by 45% vs. placebo 4/08

Phase III data suggested the therapy with Gamunex may improve physical and social functioning compared to placebo; FDA approved Gamunex 9/08

Completed its IoGen Phase III pivotal trial 2/08; Phase III data showed it failed to reach statistical significance 4/08

Missed primary endpoint in a Phase II/III trial 12/06

Data from third Phase III trial showed statistically significant improvement in subjective total sleep time 11/06; Phase III data demonstrated a statistically significant improvement 12/06; FDA wants results from a 26-week transgenic mouse carcino-genicity study included as part of the initial NDA submission 5/07; submitted an NDA 1/08; FDA accepted for filing the NDA 4/08; data demonstrated statistically significant differences relative to placebo for their primary endpoints and multiple

Began Phase III trials 7/03; French officials approved Requip; FDA accepted for filing the marketing application 4/07; received FDA approval 6/08

Began enrolling patients in two Phase III trials 1/07; started a Phase III program 5/07

Pivotal data showed significant efficacy in reducing ADHD symptoms compared to placebo 5/08

Phase III data showed that 95% of children taking Vyvanse daily for 12 months had overall improvement 5/07; submitted an sNDA 7/07; FDA granted marketing approval for use in adults 4/08; Phase III data showed significant improvements in adult symptoms; it met all safety and efficacy endpoints 5/08

Phase III data demonstrated that the drug, in combination with other anti-epileptic agents, significantly reduced the frequency of partial seizures in patients with refractory partial epilepsy 9/08

Phase III data showed statistically significant improvement over placebo 9/08

Began a Phase III program in the U.S. 9/07

Treated patients in the first of several studies in an ongoing Phase III program 11/07; began its second Phase III trial 12/07; Phase III data showed that 50% of patients reported good to excellent global improvement and demonstrated a strong dose-response effect 5/08

Filed NDA with FDA 4/05; pivotal Phase III trial demonstrated significantly improved clinical outcomes and reduced symptoms 2/06; FDA issued an approvable letter that said certain undisclosed conditions must be met before it could be approved 3/06; clinical data showed it maintained reduction of chorea up to 80 weeks in patients who completed treatment in a 13-week trial 5/07; FDA approved Xenazine 8/08

Plans to file NDA based on positive Phase III data showing it reached all of its primary endpoints 1/07; Phase III data showed the drug relieved migraine pain within 30 minutes 6/07; submitted an NDA 7/07

Began pivotal Phase III 8/05; reached agreement with FDA on SPA for 310-patient pivotal Phase III trial that began in August 11/05

Started a Phase II/III trial 6/07; started dosing in a Phase II/III trial for women with relapsing-remitting MS 7/07

Achieved its primary endpoint in a second Phase III trial 12/07; submitted NDA to the FDA 6/08; Phase III data showed the drug provides effective around-the-clock analgesia in a formulation designed to resist common methods of misuse and abuse 8/08; in an unofficial vote, more than half of 19 federal advisers said the data were sufficient in showing that Remoxy would be less susceptible to abuse and misuse than other currently marketed therapies 11/08; FDA issued complete response letter 12/08

Began another Phase III trial 12/06